» Articles » PMID: 30047820

Efficacy of Vortioxetine on the Physical Symptoms of Major Depressive Disorder

Overview
Publisher Sage Publications
Specialty Pharmacology
Date 2018 Jul 27
PMID 30047820
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Efficacy has been proven for vortioxetine in short-term and long-term treatment of major depressive disorder (MDD), with broad beneficial effects on emotional, physical and cognitive symptoms. Limited specific data on the effects of vortioxetine on depression-related physical symptoms have been published.

Methods: A meta-analysis was carried out of five short-term multinational, double-blind, placebo-controlled studies. These studies were conducted in a total of 2105 adult MDD outpatients (18-75 years) with a major depressive episode of ⩾3 months' duration. Only patients treated with a dose of 5 or 10 mg vortioxetine (therapeutic doses) or placebo were included in this analysis. Efficacy assessment of vortioxetine on the physical symptoms of depression included all items of the Hamilton Depression Scale (HAM-D) assessing physical symptoms, and all somatic items in the Hamilton Anxiety Scale (HAM-A). A subgroup analysis in MDD patients with coexisting anxiety symptoms (i.e. those with a HAM-A ⩾20 at baseline) was also performed.

Results: A significant improvement ( p<0.05) of vortioxetine versus placebo was observed on all HAM-D items measuring physical symptoms, except for the somatic gastrointestinal symptoms and loss of weight items. Significant effects were also observed on the HAM-A somatic items: general somatic symptoms, gastrointestinal symptoms, and autonomic symptoms. In patients with a high baseline level of anxiety, a significant effect of vortioxetine was also observed on the physical symptoms of depression.

Conclusions: These analyses indicate that patients with MDD, including those with a high level of anxiety symptoms, have significant improvements in MDD-associated physical symptoms when treated with vortioxetine.

Citing Articles

Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies.

DelBello M, Findling R, Huss M, Necking O, Petersen M, Schmidt S Eur Child Adolesc Psychiatry. 2024; .

PMID: 39240359 DOI: 10.1007/s00787-024-02560-1.


Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study.

Christensen M, Canellas F, Loft H, Montejo A Neuropsychiatr Dis Treat. 2024; 20:1475-1489.

PMID: 39100571 PMC: 11297586. DOI: 10.2147/NDT.S473056.


Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study.

Di Nicola M, Adair M, Rieckmann A, Christensen M C J Psychopharmacol. 2024; 38(7):615-623.

PMID: 39077889 PMC: 11290038. DOI: 10.1177/02698811241260996.


Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China Study.

Wang G, Si T, Rieckmann A, Ma J, Christensen M Neuropsychiatr Dis Treat. 2024; 20:1211-1223.

PMID: 38863483 PMC: 11166150. DOI: 10.2147/NDT.S460408.


Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine.

Cuomo A, Aguglia A, de Berardis D, Ventriglio A, Gesi C, Fagiolini A Ann Gen Psychiatry. 2024; 23(1):20.

PMID: 38755657 PMC: 11097484. DOI: 10.1186/s12991-024-00505-1.


References
1.
Hamilton M . Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry. 1989; 154:201-6. DOI: 10.1192/bjp.154.2.201. View

2.
McClintock S, Husain M, Wisniewski S, Nierenberg A, Stewart J, Trivedi M . Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011; 31(2):180-6. PMC: 3677201. DOI: 10.1097/JCP.0b013e31820ebd2c. View

3.
Hung C, Weng L, Su Y, Liu C . Depression and somatic symptoms scale: a new scale with both depression and somatic symptoms emphasized. Psychiatry Clin Neurosci. 2006; 60(6):700-8. DOI: 10.1111/j.1440-1819.2006.01585.x. View

4.
Hedlund P . The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl). 2009; 206(3):345-54. PMC: 2841472. DOI: 10.1007/s00213-009-1626-0. View

5.
Baldwin D, Florea I, Jacobsen P, Zhong W, Nomikos G . A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord. 2016; 206:140-150. DOI: 10.1016/j.jad.2016.07.015. View